Tibor Jozsef Kovacsovics MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Join to View Full Profile
3181 SW Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-5058
Fax+1 801-585-0309
Dr. Kovacsovics is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1994- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1991
Geneva University HospitalInternal Medicine, 1988 - 1990- Geneva University HospitalInternal Medicine, 1985 - 1988
- University of Lausanne (Institute of Biochemistry)Internal Medicine, 1982 - 1985
University of Geneva Faculty of MedicineClass of 1981
Certifications & Licensure
AZ State Medical License 2023 - 2027
UT State Medical License 2012 - 2026
OR State Medical License 2003 - 2025
Swiss Board for Hematology and Medical Oncolocy
Clinical Trials
- Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2009 Jun 01
- Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients Start of enrollment: 2013 Jul 01
- A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsMenin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Martha L Arellano, Michael J Thirman, John F DiPersio, Maël Heiblig, Eytan M Stein
Blood. 2025-08-28 - 1 citationsA Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.Eric D Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow
Cancer Research Communications. 2025-07-01 - 3 citationsTP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL.Ibrahim Aldoss, Shanpeng Li, Jianying Zhang, Mary C Clark, Vaibhav Agrawal
Blood Advances. 2025-05-13
Journal Articles
- A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AMLEytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Abstracts/Posters
- A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...Tibor Kovacsovics, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...Tibor Kovacsovics, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Amyloidosis Support GroupsJuly 24th, 2019
Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, TreatmentMarch 19th, 2018
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLMarch 15th, 2018- Join now to see all
Other Languages
- French, German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
